My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2009
Volume 19 Issue 2
Top Stories
Candidiasis Guidelines Updated

New guidelines for the management of candidiasis provide updated data on the appropriate use of echinocandins and expanded spectrum azoles in the management of candidemia and mucosal candidiasis.   

The guidelines recommend echinocandin for patients with moderate to severe illness or those who have had recent azole exposure. However, azoles should not be used for empirical therapy in patients who have received an azole for prophylaxis. 

Early initiation of effective antifungal therapy is crucial in the successful treatment of candidemia.  Fluconazole continues to be the standard therapy for patients with candidemia and should be considered as the first-line of treatment for mild to moderate conditions.  

Preferred treatments for osteoarticular, CNS, vulvovaginal, and urinary tract infections candidiasis were also addressed throughout the document.

The guidelines’ performance measures emphasize that all patients with candidemia should undergo dilated ophthalmological evaluation.  This process helps determine whether or not patients with endophthalmitis need surgery or local therapy.  Antifungal therapy should also be performed on all patients with candidemia within 24 hours after a positive blood culture followed by systemic antifungal therapy.  Blood cultures should be obtained daily until the condition is no longer present. 

The candidiasis guidelines are available online. Other IDSA guidelines also are available on the Standards, Practice Guidelines, and Statements page of IDSA's website.


How useful is this article?

Next Article >

Post a comment

Your name:

Your comment:


Top Stories
Candidiasis Guidelines Updated
IDSA Journal Club
From the President
Vaccine Science Prevails
Patient Care and Science
EIN Considers Alternatives to Acyclovir During Shortage
Updated Rotavirus Recommendations Include New Vaccine
ACIP Changes Recommendations for Anthrax, Hepatitis A Vaccines
Drug Approvals, Recalls, Adverse Events Update
Practice Management
CMS Sending Clinicians Reports on their Medicare Costs
How to Put Health IT to Work in Your Practice
Policy and Advocacy
Federal HAI Prevention Plan is “Important First Step”
Stimulus Funding May Go Toward ID Research, HIV/AIDS Prevention
HIVMA Urges Medicare to Cover Treatment of Facial Lipodystrophy
Advocacy Update: IDSA Expresses Concern About State Lyme Disease Bills
Education and Training
SHEA Offers California Epidemiology Course
You and Your Colleagues
Welcome New IDSA Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.